Search results for "In patient"

showing 10 items of 2141 documents

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

2021

[Background & Aims] Non-invasive scoring systems (NSS) are used to identify patients with non-alcoholic fatty liver disease (NAFLD) who are at risk of advanced fibrosis, but their reliability in predicting long-term outcomes for hepatic/extrahepatic complications or death and their concordance in cross-sectional and longitudinal risk stratification remain uncertain.

0301 basic medicineAdultMalemedicine.medical_specialtyCirrhosisConcordanceSettore MED/12 - GASTROENTEROLOGIAHFSDiseaseBARDGastroenterologySeverity of Illness IndexTime03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePredictive Value of TestsInternal medicineNFSmedicineHumansIn patientAPRINSSHepatologybusiness.industryFatty liverNASHReproducibility of ResultsMiddle Agedmedicine.diseasePrognosisAPRI BARD FIB-4 HFS NASH NFS NSS Adult Area Under Curve Cross-Sectional Studies Female Humans Liver MaleMiddle Aged Non-alcoholic Fatty Liver DiseasePrognosis ROC CurveReproducibility of Results Research Design Severity of Illness Index Predictive Value of Tests Time030104 developmental biologyCross-Sectional StudiesLiverROC CurveResearch DesignArea Under CurveCohortAPRI; BARD; FIB-4; HFS; NASH; NFS; NSSFIB-4030211 gastroenterology & hepatologyFemalebusinessLiver cancerJournal of hepatology
researchProduct

Secukinumab efficacy in the treatment of nail psoriasis: a case series

2018

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis (PsA), and can significantly impair quality of life (QoL). It is typically difficult to treat compared with skin lesions, although several conventional treatment options are available. The aim of this article is to describe our experience in the treatment of nail psoriasis with secukinumab in a case series. Fifteen patients (11 males and 4 females), with moderate-severe plaque psoriasis and nail psoriasis, eligible for systemic therapy, and received secukinumab. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) assessed cutaneous severity. Nail Psoriasis Severity Index (…

0301 basic medicineAdultMalemedicine.medical_specialtyDermatologyNail psoriasisAntibodies Monoclonal HumanizedSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisNail Diseases0302 clinical medicineQuality of lifePsoriasisSeverity of illnessMedicineHumansPsoriasisIn patientPsoriasibusiness.industrysecukinumabfungifood and beveragesAntibodies MonoclonalMiddle Agedmedicine.diseaseNail DiseaseDermatologyhumanities030104 developmental biologyNAPSITreatment OutcomeNail diseasenail psoriasiQuality of LifeSecukinumabFemalebusinessHuman2708
researchProduct

Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodyspla…

2017

This is an observational-retrospective study comparing the real-world outcomes associated with posaconazole vs. itraconazole as prophylaxis treatments. Two hundred and ninety-three patient admissions attributable to 174 patients were included in the study. Patients were treated with itraconazole (n = 114 admissions; 39%) or posaconazole (n = 179; 61%). Antifungal prophylaxis failure (APF) due to treatment-related adverse events (in 34 out of 293 patient admissions; 11.6%) was more frequent in the posaconazole group (6.1% vs. 15.1%; P = 0.024). There were 9 patient admissions for episodes of APF due to probable/proven breakthrough fungal infection (primary endpoint): 6 and 3 in the itraconaz…

0301 basic medicineAdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsDrug-Related Side Effects and Adverse ReactionsItraconazole030106 microbiologyDermatologyNeutropenia03 medical and health sciencesInternal medicinemedicineClinical endpointHumansIn patientTreatment FailureAdverse effectAgedRetrospective StudiesInvasive Pulmonary Aspergillosisbusiness.industryMyelodysplastic syndromesGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesMyelodysplastic SyndromesFemalePre-Exposure ProphylaxisItraconazolebusinessInvasive Fungal Infectionsmedicine.drugMycoses
researchProduct

Body Mass Index and Associated Clinical Variables in Patients with Non-Celiac Wheat Sensitivity.

2019

Background: Non-Celiac Wheat Sensitivity (NCWS) is still a largely undefined condition, due to the lack of a diagnostic marker. Few data are available about the nutritional characteristics of NCWS patients at diagnosis. Aims: To evaluate the proportion of NCWS patients who were underweight, normal weight, overweight, or obese at diagnosis, and to search for possible correlations between their Body Mass Index (BMI) and other NCWS-related disease characteristics. Patients and Methods: The clinical charts of 145 NCWS patients (125 F, 20 M, mean age 37.1 &plusmn

0301 basic medicineAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaClinical variablesHLA haplotypelcsh:TX341-641autoimmune diseaseAutoimmunityDiseaseWheat HypersensitivityOverweightBody Mass Index (BMI)GastroenterologyArticleBody Mass IndexCeliac Disease (CD)03 medical and health sciencesIrritable Bowel Syndrome (IBS)0302 clinical medicineThinnessWeight lossInternal medicineHLA-DQ AntigensmedicineHumansIn patientautoimmune diseasesIrritable bowel syndromeRetrospective StudiesNutrition and Dieteticsbusiness.industrynutritional and metabolic diseasesMiddle AgedOverweightmedicine.diseasePrognosis030104 developmental biologyHaplotypesnon-celiac wheat sensitivity (NCWS)030211 gastroenterology & hepatologyFemalemedicine.symptomUnderweightbusinesslcsh:Nutrition. Foods and food supplyBody mass indexFood ScienceNutrients
researchProduct

Role of Haptoglobin as a Marker of Muscular Improvement in Patients with Multiple Sclerosis after Administration of Epigallocatechin Gallate and Incr…

2021

Here, we report on the role of haptoglobin (Hp), whose expression depends on the synthesis of interleukin 6 (IL-6), related to the pathogenesis of multiple sclerosis (MS), as a possible marker of muscle improvement achieved after treatment with the polyphenol epigallocatechin gallate (EGCG) and an increase in the ketone body beta-hydroxybutyrate (BHB) in the blood. After 4 months of intervention with 27 MS patients, we observed that Hp does not significantly increase, alongside a significant decrease in IL-6 and a significant increase in muscle percentage. At the same time, Hp synthesis is considerably and positively correlated with IL-6 both before and after treatment

0301 basic medicineAdultMalemedicine.medical_specialtyepigallocatechin gallateMultiple Sclerosisbeta-hydroxybutyratemuscleinterleukin 6Pilot ProjectsEpigallocatechin gallateMicrobiologyBiochemistryCatechinArticlePathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBeta hydroxybutyrateInternal medicinemedicineHumansIn patientInterleukin 6Muscle SkeletalMolecular Biologybiology3-Hydroxybutyric AcidHaptoglobinsbusiness.industryInterleukin-6Multiple sclerosisHaptoglobinfood and beveragesMiddle Agedmedicine.diseaseQR1-502haptoglobin030104 developmental biologyEndocrinologychemistrybiology.proteinKetone bodiesFemalebusiness030217 neurology & neurosurgeryBiomarkersBiomolecules
researchProduct

Number needed to freeze: cumulative live birth rate after fertility preservation in women with endometriosis

2021

Research question: How does the number of oocytes used affect the cumulative live birth rate in endometriosis patients who had their oocytes vitrified for fertility preservation (FP)? Design: Retrospective observational study including data from 485 women with endometriosis who underwent FP from January 2007 to July 2018. Survival curves and Kaplan-Meier plots were used to analyse the cumulative live birth rate (CLBR) according to the number of vitrified oocytes used. Data were stratified according to age, stage of the disease and ovarian surgery prior to FP (operated vs. non-operated). Endometriosis curves were compared to plots developed using elective fertility preservation (EFP) patient…

0301 basic medicineAdultmedicine.medical_specialtymedicine.medical_treatmentEndometriosisEndometriosisCystectomy03 medical and health sciences0302 clinical medicinePregnancymedicineHumansIn patientFertility preservationBirth RateSurvival analysisRetrospective Studies030219 obstetrics & reproductive medicineObstetricsbusiness.industryObstetrics and GynecologyFertility PreservationRetrospective cohort studymedicine.diseaseConfidence interval030104 developmental biologyReproductive MedicineOocytesFemaleLive birthbusinessObstetríciaDevelopmental Biology
researchProduct

Aspergilosis invasora en el paciente con enfermedad oncohematológica

2018

Invasive aspergillosis is the most common invasive fungal infection in patients with acute hematological malignancies or treated with hematopoietic stem cell transplantation due to the marked alteration of the physiological mechanisms of antifungal immunity that takes place in these situations. For this reason, antifungal prophylaxis has a relevant role in these patients. The introduction of new antifungal agents has motivated the updating of recommendations for prophylaxis and treatment in different guidelines. The objectives of this chapter are a brief review of the mechanisms of immunity against fungi, the definition of risk for developing an invasive fungal infection and an update of th…

0301 basic medicineAntifungalmedicine.drug_classbusiness.industrymedicine.medical_treatment030106 microbiologyHematopoietic stem cell transplantationAspergillosismedicine.diseaseMicrobiology03 medical and health sciencesInfectious DiseasesHematological DiseasesImmunityImmunologymedicineIn patientbusinessRevista Iberoamericana de Micología
researchProduct

Identification of circumferential regional heterogeneity of ascending thoracic aneurysmal aorta by biaxial mechanical testing

2019

Abstract Ascending thoracic aortic aneurysm (ATAA) in patients with bicuspid aortic valve (BAV) can present an asymmetrical aortic dilatation compared with patients with tricuspid aortic valve (TAV). This pattern of aneurysm dilatation led us to hypothesize that biomechanical differences likely induced by regional heterogeneity of material properties can underlie the observed asymmetric enlargement discrepancies between BAV ATAA and TAV ATAA. This study aimed to characterize the mechanical properties and associated aortic tissue stiffness changes along the circumferential direction of aortic rings collected from surgically-repaired patients with ATAA. Biaxial material testing was performed …

0301 basic medicineAortic valveMaleMaterial parameterBicuspid aortic valveHeart Valve DiseasesAorta Thoracic030204 cardiovascular system & hematologyThoracic aortic aneurysm03 medical and health sciences0302 clinical medicineBicuspid aortic valveAneurysmVascular StiffnessBicuspid Aortic Valve Diseasemedicine.arteryMedicineHumansIn patientMolecular BiologyAgedAged 80 and overAortaAortic Aneurysm Thoracicbusiness.industryAscending aortic aneurysmSettore ING-IND/34 - Bioingegneria IndustrialeAnatomyMiddle Agedmedicine.diseaseSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Tissue stiffness030104 developmental biologymedicine.anatomical_structureAortic Valvecardiovascular systemFemaleTissue stiffnessCardiology and Cardiovascular MedicinebusinessBiaxial testingSettore ICAR/08 - Scienza Delle CostruzioniElastic fiberDilatation Pathologic
researchProduct

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreat…

2018

Abstract Introduction: Immunochemotherapy is standard of care treatment for previously untreated patients (pts) with advanced stage follicular lymphoma (FL). However, the majority of pts relapse, with around 20% relapsing within 2 years. Obinutuzumab (GA101; G) is a glycoengineered type II anti-CD20 monoclonal antibody (mAb) with increased antibody-dependent cell-mediated phagocytosis and cytotoxicity, and direct B-cell killing, compared with the type I mAb rituximab (R). The randomized Phase III GALLIUM study (NCT01332968) compared the efficacy and safety of G-chemotherapy (G-chemo) vs R-chemotherapy (R-chemo) in previously untreated pts with advanced stage FL. In the primary analysis (PA)…

0301 basic medicineBendamustinemedicine.medical_specialtyImmunologyFollicular lymphomaLower riskBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineObinutuzumabInternal medicineMedicineIn patientProgression-free survivalbusiness.industryCell BiologyHematologymedicine.diseaseLymphomaDiscontinuation030104 developmental biologychemistry030220 oncology & carcinogenesisbusinessmedicine.drugBlood
researchProduct

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts

2020

International audience; Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive biomarkers for response to PD-1/PD-L1 inhibitors is critical for patient selection. Expression of PD-L1 has demonstrated utility in patient selection. Tumour mutational burden (TMB) is an emerging biomarker for response to PD-1/PD-L1 inhibitors. The evaluation of this biomarker is based on the hypothesis that a high number of mutations in somatic exonic regions will lead to an increase in neoantigen production, which could then be recognised by…

0301 basic medicineCancer ResearchImmune checkpoint inhibitorsmedicine.medical_treatment[SDV]Life Sciences [q-bio]DNA Mutational AnalysisProgrammed Cell Death 1 ReceptorTumour mutational burdenBioinformaticsArticleB7-H1 Antigen03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImmune systemNeoplasmsBiomarkers TumorHumansMedicineIn patientGenetic TestingPredictive biomarkerbusiness.industryPatient SelectionCancerBiomarkerImmunotherapymedicine.disease3. Good healthBiomarker (cell)[SDV] Life Sciences [q-bio]030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationImmunotherapybusinessCD8
researchProduct